In 2013, a new class of diabetes drugs was approved by the FDA. It was hailed as a breakthrough.
The medications were called SGLT2 inhibitors. They included Invokana (canagliflozin), Farxiga, (dapagliflozin), and Jardiance (empagliflozin).
The drugs worked by causing the kidneys to remove more blood sugar.
SGLT2 inhibitors were touted as providing superior blood sugar control for type 2 diabetics with no serious side effects.… Read More